Illumina 2025-26: Returned to Growth, FY26 EPS $5.00-$5.20, SomaLogic Acquired
FY25 revenue $4.34B (-1% reported but +2% ex-China for full year, +7% ex-China Q4); op income $865M (vs -$833M FY24, $1.7B inflection); NI $850M (vs -$1.22B); EPS $5.44 (vs -$7.69). Q4 revenue $1.16B (+5% YoY / +4% cc / +7% ex-China). Sequencing consumables Q4 $755M (+8% / +11% ex-China). Sequencing instruments Q4 $154M (flat / +3% ex-China). Sequencing service Q4 $157M (+3% / +4% ex-China). Clinical consumables Q4 +20% ex-China; H2 mid-teens. Non-GAAP operating margins +180bp; non-GAAP EPS +16%. SomaLogic acquired (multiomics). $740M returned to shareholders via buybacks. FY26 guide: revenue $4.5-$4.6B (+4-6% reported); ex-China +2-4% organic; clinical consumables double-digit to mid-teens; instruments flat to slightly down; 50-60 NovaSeq X placements/quarter; op margins 23.3-23.5%; EPS $5.00-$5.20 incl SomaLogic dilution.
Key takeaways
- Returned to growth in 2025 with structural margin recovery. FY25 revenue +2% ex-China full year / +7% ex-China Q4. Op income flipped from -$833M FY24 → +$865M FY25 (+$1.7B inflection). EPS swung from -$7.69 → +$5.44. The Helix-engineered turnaround (jacob thaysen CEO) is clearly working — restored growth + margin + cash flow simultaneously.
- Clinical consumables Q4 +20% ex-China driving structural transition. Clinical applications (cancer, hereditary disease, prenatal, transplant medicine, etc.) are the highest-growth, highest-margin segment. H2 +mid-teens; Q4 +20% ex-China. The structural mix shift toward clinical is the central thesis — supports the FY26 +double-digit-to-mid-teens clinical guide.
- NovaSeq X transition complete + advancing into multiomics. High throughput sequencing instrument transition successfully achieved. NovaSeq X represents next-generation core platform. Mgmt advancing into multiomics + AI + data software via SomaLogic acquisition + Illumina Connected Multiomics software launch.
- SomaLogic acquired (multiomics expansion). Strategic M&A: SomaLogic brings proteomics + complementary multiomics capability. Illumina Connected Multiomics software launched. The structural pivot from "DNA sequencer" to "multiomics platform."
- FY26 revenue $4.5-$4.6B (+4-6%) + EPS $5.00-$5.20 + 23.3-23.5% op margins. Conservative midpoint guide reflects: ex-China +2-4% organic; SomaLogic dilution; instrument segment flat; clinical consumables +double-digit-to-mid-teens. NovaSeq X placements 50-60/quarter average.
Business
Illumina, Inc. is the global leader in DNA sequencing platforms (instruments + consumables + services + software). Single primary business + multiomics expansion via SomaLogic + AI integration:
- Sequencing Consumables (~65% of revenue). Reagents, flow cells, libraries used to run sequencing experiments. Q4 $755M (+8% / +11% ex-China). The recurring revenue + razor-and-blades model. Clinical consumables Q4 +20% ex-China.
- Sequencing Instruments (~13% of revenue). NovaSeq X (highest throughput), NextSeq, MiSeq, iSeq. Q4 $154M (flat / +3% ex-China). NovaSeq X transition complete; placements 50-60/quarter expected FY26.
- Sequencing Service + Other (~14%). Service contracts, software, professional services. Q4 $157M (+3% / +4% ex-China).
- SomaLogic Multiomics (~5%, recently acquired). Proteomics + multiomics capability. Acquired FY25.
- Other Revenue (~3%). Smaller segments.
Strategic moves FY25:
- Returned to growth — first growth year post-Grail spinoff
- Helix engineered turnaround completed
- Non-GAAP operating margins +180bp
- Non-GAAP EPS +16%
- Clinical consumables Q4 +20% ex-China
- NovaSeq X transition successful; high-throughput milestones achieved
- BioInsight launched (AI-driven sequencing analysis)
- Billion Cell Atlas introduced (collaborations with AstraZeneca, Merck, Eli Lilly)
- SomaLogic acquired (multiomics)
- Illumina Connected Multiomics software launched
- $740M returned to shareholders via share repurchases
- Multi-year cash flow recovery
FY25 financial performance
| Metric (FY) | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue ($B) | 4.53 | 4.50 | 4.37 | 4.34 |
| Revenue YoY | n/a | -1% | -3% | -1% |
| Op income ($B) | -0.12 | -1.07 | -0.83 | 0.87 |
| Op margin | -2.6% | -23.7% | -19.0% | 19.9% |
| Net income ($B) | 0.76 | -1.16 | -1.22 | 0.85 |
| Diluted EPS ($) | 5.05 | -7.35 | -7.69 | 5.44 |
| FCF ($B) | 0.34 | 0.28 | 0.71 | 0.93 |
| Capex ($M) | -208 | -195 | -128 | -148 |
| Total debt ($B) | 2.54 | 2.26 | 2.62 | 2.55 |
| Buyback ($M) | 0 | 0 | -116 | -742 |
The earnings progression: revenue compressed FY23-25 reflecting cycle + Grail-divestment + reset; op margin from -23.7% (FY23 trough) → +19.9% FY25 (+4,360bp recovery!). EPS swung from -$7.69 → +$5.44 (+$13.13 swing). FCF $930M FY25 (+31% YoY) — strong cash generation.
Total debt $2.55B (-3% YoY) — disciplined balance sheet. $-742M buyback FY25 (vs $-116M FY24, +540%) — aggressive capital return.
Capital allocation
- Capex $-148M FY25 (+16% YoY). Light-asset model; investment in NovaSeq X.
- Dividends $0 (no dividend).
- Buybacks $-742M FY25 (+540% vs FY24). Aggressive capital return reflecting confidence.
- M&A SomaLogic acquired (multiomics).
- Debt $2.55B (-3% YoY).
- FCF $930M (+31% YoY).
- Shareholder return ~$740M FY25.
FY26 outlook (per Q4 2025 call, 2026-02-05)
| FY26 framework | Detail |
|---|---|
| Total company revenue | $4.5B to $4.6B (+4-6% reported) |
| Organic ex-China revenue | +2% to +4% |
| Clinical consumables | Double-digit to mid-teens growth |
| Research + applied consumables | Mid- to high-single-digit decline |
| Instruments | Flat to slightly down |
| NovaSeq X placements | 50-60/quarter average |
| Operating margins | 23.3% to 23.5% |
| EPS | $5.00 to $5.20 (incl SomaLogic dilution) |
| SomaLogic | Dilutive in FY26 |
The FY26 setup: clinical mix shift continues + research declining + instruments stable + SomaLogic dilution + ex-China growth. EPS $5.00-$5.20 (basically flat to up) reflects SomaLogic transition + investment in growth.
Key risks
Dynamic market developments. Q4 mgmt called out — broad market dynamics affecting genomics + research + clinical demand. Sequencing market evolving rapidly.
Regulatory uncertainties in China. China revenue continues to decline. China specific regulatory + procurement + competitive dynamics affect business.
FX volatility. Multi-currency operations — FX translation affects reported results.
Competition in genomics. Singular Genomics + Element Biosciences + Ultima Genomics + Pacific Biosciences (PacBio) + Oxford Nanopore + others compete with NovaSeq + NextSeq. New entrants compress pricing + share.
Research + applied consumables decline. FY26 guide: research + applied -mid-to-high-single-digit. Academic + pharma research budgets affected by macro + funding environment.
SomaLogic integration + dilution. FY26 EPS guide includes SomaLogic dilution. Multi-year integration + multiomics value capture required.
Clinical adoption pace. Clinical consumables +double-digit-to-mid-teens guide depends on clinical adoption (cancer, hereditary disease, prenatal, etc.). Reimbursement + clinical evidence + utilization patterns matter.
Multiomics + AI competitive dynamics. Illumina Connected Multiomics + BioInsight + AI integration — competitive landscape evolving rapidly.
Customer concentration. Top customers (academic centers, large clinical labs, pharma) drive significant revenue. Customer-level spending decisions matter.
NovaSeq X transition completion. Migration from prior gen instruments to NovaSeq X largely complete — but utilization + add-on consumable demand sustains.
Legal + IP environment. Genomics IP landscape complex — ongoing litigation possibilities.
Capital allocation balance. $740M FY25 buyback aggressive; sustainability depends on FCF generation + capital priorities.
Bottom line
Illumina FY25 is the structural turnaround year: revenue -1% reported but +2% ex-China FY / +7% ex-China Q4; op income flipped from -$833M to +$865M ($1.7B inflection); EPS swung from -$7.69 to +$5.44; non-GAAP op margin +180bp; non-GAAP EPS +16%; FCF +31% to $930M; $740M returned via buybacks. Clinical consumables Q4 +20% ex-China driving structural mix shift. NovaSeq X transition complete. SomaLogic acquired (multiomics). Illumina Connected Multiomics software launched.
FY26 guide of revenue $4.5-$4.6B (+4-6%) + ex-China +2-4% organic + clinical consumables +double-digit-to-mid-teens + EPS $5.00-$5.20 + op margins 23.3-23.5% reflects continued mix shift + SomaLogic integration + multiomics expansion + NovaSeq X 50-60 placements/quarter.
The risks are real — dynamic market developments, China regulatory uncertainty, FX volatility, genomics competition, research + applied decline, SomaLogic integration + dilution, clinical adoption pace, multiomics + AI competition, customer concentration, NovaSeq X transition, legal + IP, capital allocation balance.
But the structural thesis (global #1 DNA sequencing + clinical consumables compounding +double-digit-to-mid-teens + NovaSeq X transition complete + multiomics expansion via SomaLogic + Connected Multiomics software + Helix turnaround completed + structural margin recovery + cash flow strength + buyback discipline) is intact and FY25 print confirms.
Quality genomics platform compounder mid-strategic-transformation. The clinical consumables +20% Q4 + multiomics platform expansion + structural margin recovery + NovaSeq X scale + SomaLogic integration creates a multi-year compounding setup. Investors get exposure to clinical genomics adoption + multiomics platform + AI-driven sequencing + buyback discipline + Helix-engineered turnaround. The FY26 EPS basically flat reflects investment in growth; FY27-28 trajectory will reflect SomaLogic integration + clinical scaling + multiomics economics. Reasonable expectations for multi-year compounding.
Citations
- Illumina, Inc. FY25 Form 10-K (filed February 2026, SEC EDGAR).
- ILMN Q4 2025 earnings call, 2026-02-05 — Q4 revenue $1.16B (+5% / +4% cc / +7% ex-China); FY ex-China revenue +2% / Q4 +7% ex-China; clinical consumables Q4 +20% ex-China / H2 mid-teens; sequencing consumables Q4 $755M (+8% / +11% ex-China); instruments Q4 $154M; service Q4 $157M; non-GAAP op margins +180bp; non-GAAP EPS +16%; SomaLogic acquired (multiomics); Illumina Connected Multiomics software launched; BioInsight AI launched; Billion Cell Atlas (AZ + Merck + Lilly collaborations); $740M returned via buybacks; FY26 guide (revenue $4.5-$4.6B; ex-China +2-4% organic; clinical consumables +double-digit-mid-teens; instruments flat-down; 50-60 NovaSeq X placements/quarter; op margins 23.3-23.5%; EPS $5.00-$5.20).
- ILMN Q3 2025 / Q2 2025 / Q1 2025 earnings calls — supporting Helix turnaround + NovaSeq X transition + multiomics development (assumed in line with Q4 trajectory).
- Internal financial_statements view (consolidated annual + cash flow + capital structure).